Cargando…

p130Cas Is Correlated with EREG Expression and a Prognostic Factor Depending on Colorectal Cancer Stage and Localization Reducing FOLFIRI Efficacy

p130 Crk-associated substrate (p130Cas) is associated with poor prognosis and treatment resistance in breast and lung cancers. To elucidate p130Cas functional and clinical role in colorectal cancer (CRC) progression/therapy resistance, we performed cell culture experiments and bioinformatic/statisti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumbrink, Jörg, Li, Pan, Pók-Udvari, Agnes, Klauschen, Frederick, Kirchner, Thomas, Jung, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625396/ https://www.ncbi.nlm.nih.gov/pubmed/34830244 http://dx.doi.org/10.3390/ijms222212364

Ejemplares similares

Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance
por: Torlot, Lucien, et al.
Publicado: (2022)

Polymorphism in the EREG gene confers susceptibility to tuberculosis
por: Cao, Wen, et al.
Publicado: (2019)

The Role of EREG/EGFR Pathway in Tumor Progression
por: Cheng, Wan-Li, et al.
Publicado: (2021)

Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer
por: Lee, Michael S, et al.
Publicado: (2016)

Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC)
por: El-Deiry, Wafik S., et al.
Publicado: (2019)

Olfactomedin 4 associates with expression of differentiation markers but not with properties of cancer stemness, EMT nor metastatic spread in colorectal cancer
por: Jaitner, Stefanie, et al.
Publicado: (2022)

BMP7 and EREG Contribute to the Inductive Potential of Dental Mesenchyme
por: Gao, Bo, et al.
Publicado: (2015)

EREG is a risk factor for the prognosis of patients with cervical cancer
por: Li, Tianye, et al.
Publicado: (2023)

Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter
por: Qu, X, et al.
Publicado: (2016)

Efficacy and safety of FOLFIRI and biotherapy versus FOLFIRI alone for metastatic colorectal cancer patients: A meta-analysis
por: Jiang, Yangbo, et al.
Publicado: (2017)

Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice
por: Ottaiano, Alessandro, et al.
Publicado: (2019)

Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer
por: Hamaguchi, Tetsuya, et al.
Publicado: (2019)

Syringic acid mitigates isoproterenol‐induced cardiac hypertrophy and fibrosis by downregulating Ereg
por: Han, Xiongyi, et al.
Publicado: (2022)

Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer
por: Joulain, F, et al.
Publicado: (2013)

A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
por: Gorbunova, Vera, et al.
Publicado: (2018)

Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
por: Gorbunova, Vera, et al.
Publicado: (2019)

FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer
por: Carola, Candice, et al.
Publicado: (2018)

Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3
por: Fischer, Laura E., et al.
Publicado: (2022)

Balanitis associated with FOLFIRI chemotherapy
por: Micevic, Goran, et al.
Publicado: (2017)

Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI
por: De Mattia, Elena, et al.
Publicado: (2019)

Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer
por: Kim, Jinchul, et al.
Publicado: (2021)

RHOA GTPase Controls YAP-Mediated EREG Signaling in Small Intestinal Stem Cell Maintenance
por: Liu, Ming, et al.
Publicado: (2017)

Blocking EREG/GPX4 Sensitizes Head and Neck Cancer to Cetuximab through Ferroptosis Induction
por: Jehl, Aude, et al.
Publicado: (2023)

Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma
por: Niogret, Julie, et al.
Publicado: (2020)

EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy
por: Liu, Shuli, et al.
Publicado: (2020)

Puromycin aminonucleoside modulates p130Cas of podocytes
por: Ha, Tae-Sun, et al.
Publicado: (2012)

XELIRI compared with FOLFIRI as a second-line treatment in patients with metastatic colorectal cancer
por: CUI, CHENGXU, et al.
Publicado: (2014)

Predictive factors for 6 vs 12 cycles of Folfiri-Bevacizumab in metastatic colorectal cancer
por: Formica, Vincenzo, et al.
Publicado: (2017)

Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer
por: Devaux, Madeline, et al.
Publicado: (2019)

Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer
por: Rong, Xuetong, et al.
Publicado: (2022)

A post-marketing safety study of ramucirumab with FOLFIRI in patients with metastatic colorectal cancer
por: Masuishi, Toshiki, et al.
Publicado: (2022)

A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI
por: Chau, Ian, et al.
Publicado: (2014)

Efficacy and safety of FOLFIRI/aflibercept in second‐line treatment of metastatic colorectal cancer in a real‐world population: Prognostic and predictive markers
por: Fernández Montes, Ana, et al.
Publicado: (2019)

Biomarker alterations associated with distinct patterns of metastatic spread in colorectal cancer
por: Michl, M., et al.
Publicado: (2020)

FOLFIRI(®) and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms
por: Bécouarn, Yves, et al.
Publicado: (2014)

Metastatic Colorectal Cancer Treated with Herbal Pharmacopuncture during FOLFIRI Chemotherapy: A Case Report
por: Lee, Jung-Woo, et al.
Publicado: (2014)

Necrotising fasciitis in a patient treated with FOLFIRI-aflibercept for colorectal cancer: a case report
por: Gonzaga-López, A, et al.
Publicado: (2017)

Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting()()()
por: Ma, Cheng-Jen, et al.
Publicado: (2018)

Phase I study of napabucasin in combination with FOLFIRI + bevacizumab in Japanese patients with metastatic colorectal cancer
por: Taniguchi, Hiroya, et al.
Publicado: (2021)

Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance
por: Watanabe, Jun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b1ofdb7cnt967dv23rl6nr6lri